SCHEMBL6609080

SCHEMBL6609080

CNS(=O)(=O)c1ccc(-c2cc[c]cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
GAA P10253 1/20 0.55
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA3 P07451 2/20 0.53
CA4 P22748 2/20 0.53
CA6 P23280 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA13 Q8N1Q1 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
LMNA P02545 3/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 3/20 0.50
KIF11 P52732 1/20 0.50
NR3C2 P08235 1/20 0.44
DRD1 P21728 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167548 0.87 SMN1; SMN2 (0.58) SMN1; SMN2GAACA12CA1CA2
SCHEMBL8080277 0.87 SMN1; SMN2 (0.70) SMN1; SMN2GAACA12CA1CA2
SCHEMBL2223018 0.80 GAA (0.47) SMN1; SMN2GAACA12CA1CA2
SCHEMBL7629070 0.80 SMN1; SMN2 (0.80) SMN1; SMN2GAACA12CA1CA2
SCHEMBL3935740 0.79 ALDH1A1 (0.59) SMN1; SMN2GAACA12CA1CA2
SCHEMBL3906959 0.79 NR3C2 (0.61) SMN1; SMN2GAACA12CA1CA2
SCHEMBL6609278 0.78 SMN1; SMN2 (0.57) SMN1; SMN2GAACA12CA1CA2
SCHEMBL15575337 0.78 SMN1; SMN2 (0.57) SMN1; SMN2GAACA12CA1CA2
SCHEMBL746134 0.77 PTGS2 (0.50) KIF11PTGS2
SCHEMBL16719763 0.77 SMN1; SMN2 (0.43) SMN1; SMN2GAACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US claimed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP claimed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO claimed
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 SMN1; SMN2 1918/4885GAA 364/4885CA12 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.